TScan Therapeutics beat estimated earnings by 33.33%, reporting an EPS of $-0.18 versus an estimate of $-0.27. Revenue was up $1.90 million from the same period last year. The company beat on EPS by ...

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of Phase ...

Hawk dealership is truly a five star dealerships. Nothing but the best service I was in and out service was quick all around top-notch. Hawk dealership is truly a five star dealerships. Hawk ...

Black Hawk Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar ...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously ...